晚期肾细胞癌患者中可操作的肠道微生物检查点 MAdCAM-1.pdf

1、The actionable microbial gut checkpoint MAdCAM-1 in patients with advanced renal cell carcinomaCarolina Alves Costa Silva,MD,PhDOncoclnicas Group/Oswaldo Cruz Foundation/Federal University of Bahia,Salvador Bahia,BrazilGustave Roussy Cancer Campus,Villejuif,FranceThe gut microbiota impact cancer imm

2、unosurveillanceAdapted from Hanahan et al.,Cancer Discov.2022Gut dysbiosis disrupts the ileal madcam-1/47 axisFidelle,Rauber and Alves Costa Silva et al.Science 2023High MAdCAM-1 levels are associated with improved survival irrespective of treatment arm SLIDE DIMENSIONS SHOULD FOLLOW 16:9 RATIO Prog

3、ression-Free SurvivalOverall SurvivalSaliby et al.ASCO 2025Persistently low circulating MAdCAM-1 levels at 3 months of treatment start are associated with poor survivalPFSOSHR(95%CI)p-valueHR(95%CI)p-valueHigh-High0.53(0.37,0.76)0.0010.34(0.23,0.52).001Low-High0.59(0.36,0.98)0.0410.64(0.37,1.12)0.11

4、6High-Low0.52(0.29,0.92)0.0240.49(0.26,0.92)0.026Low-LowrefrefrefrefTable 1.Cox proportional hazards models for longitudinal C1-C3 sMAdCAM-1 categories.Low MAdCAM-1 levels are associated with distinct pro-inflammatory microbes,prototypical Enterocloster spp.and SIG1Key messages for circulating MAdCA

5、M-1 levels Prognostic biomarker for RCC Low levels are associated with poorer survival distinct pro-inflammatory microbial-immune phenotype Dynamic biomarker for tracking dysbiosis-driven immune dysregulation,and Potential therapeutic target for microbiota-directed interventions in treatment-resistant RCCI am thankful to study participants&caregivers and my rich scientific commensalismCarolina Alves Costa Silva,MD,PhDMarc MachaalaniCaiwei ZhongWanling XieLaurence ZitvogelLaurence AlbigesToni K.ChoueiriRMS